➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Moodys
AstraZeneca
Colorcon

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

NUVARING Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Nuvaring patents expire, and what generic alternatives are available?

Nuvaring is a drug marketed by Organon Sub Merck and is included in one NDA.

The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.

Drug patent expirations by year for NUVARING
Drug Prices for NUVARING

See drug prices for NUVARING

Drug Sales Revenue Trends for NUVARING

See drug sales revenues for NUVARING

Recent Clinical Trials for NUVARING

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrea Roe, MD, MPHPhase 4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 4
University of WashingtonPhase 4

See all NUVARING clinical trials

Pharmacology for NUVARING
Paragraph IV (Patent) Challenges for NUVARING
Tradename Dosage Ingredient NDA Submissiondate
NUVARING RING;VAGINAL ethinyl estradiol; etonogestrel 021187 2013-06-17

US Patents and Regulatory Information for NUVARING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Sub Merck NUVARING ethinyl estradiol; etonogestrel RING;VAGINAL 021187-001 Oct 3, 2001 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NUVARING

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1453521 93156 Luxembourg   Start Trial PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1214076 C01214076/01 Switzerland   Start Trial PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
0398460 C300221 Netherlands   Start Trial PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Moodys
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.